InvestorsHub Logo
Followers 7
Posts 289
Boards Moderated 0
Alias Born 12/11/2013

Re: None

Thursday, 03/18/2021 10:31:32 AM

Thursday, March 18, 2021 10:31:32 AM

Post# of 402839
Gee I wonder if South Africa might be interested in buying an effective therapuetic.....

AstraZeneca vaccine only 10% effective against variant in South Africa

Last month, South Africa halted the rollout of AstraZeneca and Oxford University’s Covid-19 vaccine after a study showed it didn’t protect against mild-to-moderate cases caused by the B.1.351 variant, which is now widespread in the country. Now we’re getting a look at the data.

While the vaccine was showing an efficacy of around 75% prior to the spread of B.1.351, a new analysis suggested the vaccine is only 10.4% effective against the variant, according to data published in the New England Journal of Medicine. 

The study enrolled 2,026 HIV-negative adults, about half of whom were randomized to receive the vaccine. A total of 42 came down with Covid-19, and 39 of those cases were caused by the B.1.351 variant. Overall efficacy in this group, which consisted mostly of cases linked to the variant, was just under 22%.

“What this data don’t tell us is whether or not this vaccine might still protect at least against severe Covid-19,” Shabir Madhi, chief investigator of the study, said during a briefing last month.

Two days after halting the country’s rollout of AstraZeneca and Oxford University’s Covid-19 vaccine, South Africa’s government said it was considering selling or exchanging the doses it had already received.

https://endpts.com/covid-19-roundup-alnylam-vir-quietly-deprioritize-covid-19-drug-data-suggest-astrazenecas-vaccine-is-only-10-4-effective-against-new-variant/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News